AG
BIO icon

Aperio Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Aperio Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$22.6M Buy
38,854
+431
+1% +$245K 0.07% 284
2020
Q3 		$19.8M Buy
38,423
+4,278
+13% +$2.17M 0.07% 274
2020
Q2 		$15.4M Buy
34,145
+5,152
+18% +$2.27M 0.06% 327
2020
Q1 		$10.2M Buy
28,993
+8,798
+44% +$3.23M 0.04% 401
2019
Q4 		$7.47M Buy
20,195
+405
+2% +$143K 0.03% 589
2019
Q3 		$6.58M Buy
19,790
+630
+3% +$206K 0.03% 617
2019
Q2 		$5.99M Sell
19,160
-2,142
-10% -$641K 0.02% 644
2019
Q1 		$6.51M Sell
21,302
-26
-0.1% -$7.02K 0.03% 602
2018
Q4 		$4.95M Buy
21,328
+2,388
+13% +$641K 0.03% 648
2018
Q3 		$5.93M Sell
18,940
-16
-0.1% -$4.97K 0.03% 621
2018
Q2 		$5.47M Sell
18,956
-171
-0.9% -$47.2K 0.03% 625
2018
Q1 		$4.78M Buy
19,127
+235
+1% +$59.8K 0.02% 674
2017
Q4 		$4.51M Sell
18,892
-551
-3% -$134K 0.02% 672
2017
Q3 		$4.32M Buy
19,443
+254
+1% +$57.2K 0.02% 652
2017
Q2 		$4.34M Buy
19,189
+1,976
+11% +$431K 0.03% 644
2017
Q1 		$3.43M Buy
17,213
+2,470
+17% +$476K 0.02% 679
2016
Q4 		$2.69M Sell
14,743
-3,096
-17% -$528K 0.02% 717
2016
Q3 		$2.92M Buy
17,839
+4,309
+32% +$654K 0.02% 706
2016
Q2 		$1.94M Buy
13,530
+4,901
+57% +$699K 0.02% 818
2016
Q1 		$1.18M Buy
8,629
+783
+10% +$103K 0.01% 974
2015
Q4 		$1.09M Buy
7,846
+2,684
+52% +$372K 0.01% 984
2015
Q3 		$693K Buy
5,162
+549
+12% +$79K 0.01% 1134
2015
Q2 		$695K Buy
4,613
+1,677
+57% +$240K 0.01% 1145
2015
Q1 		$397K Buy
2,936
+635
+28% +$78.7K ﹤0.01% 1404
2014
Q4 		$277K Sell
2,301
-145
-6% -$16.7K ﹤0.01% 1555
2014
Q3 		$277K Buy
2,446
+210
+9% +$24.9K ﹤0.01% 1432
2014
Q2 		$268K Buy
2,236
+167
+8% +$20.4K ﹤0.01% 1453
2014
Q1 		$265K Buy
+2,069
New +$265K ﹤0.01% 1705
2013
Q4 		– Sell
-1,842
Closed -$224K – 1651
2013
Q3 		$217K Buy
+1,842
New +$217K ﹤0.01% 1602

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Aperio Group's BIO Position: Q4 2020 in Review

Aperio Group increased its Bio-Rad Laboratories Class A (BIO) stake by 1.1% in Q4 2020, buying an estimated $245K and bringing the position to 38,854 shares worth $22.6M. The position accounts for 0.07% of the portfolio, ranked #284.

Aperio Group first reported a position in BIO in Q3 2013 and has held it in 29 quarters since. 491 funds tracked by Wall St. Rank hold BIO as of Q4 2020.

  • Aperio Group held 38,854 shares of Bio-Rad Laboratories Class A worth $22.6M as of Q4 2020.
  • Aperio Group bought 431 Bio-Rad Laboratories Class A shares in Q4 2020, an estimated $245K.
  • Bio-Rad Laboratories Class A made up 0.07% of Aperio Group's portfolio in Q4 2020, its #284 holding.
  • Aperio Group first reported a position in Bio-Rad Laboratories Class A in Q3 2013 and has held it in 29 quarters since.
  • 491 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.